In conclusion, this work describes the opposed actions of chemotherapy and ETCI inhibitors on immune system modulation, providing a non-canonical function of ETCI in the regulation of CD39 and PD-L1 and a rationale to improve the anti-tumor response in AML including combinations with immune checkpoint therapies. Here, ENTPD1 is linked to neoplasm.